Renal Immunology
腎臓免疫
In the kidney, toxic waste products of metabolism and salt are removed
from the blood. In addition, the kidney have functions as a size-selective
filter that retains molecules above -50 kDa in blood. Nephrotic syndrome
comprise symptoms of proteina, hypoalbuminemia, and edema, which are caused
by the disruption of kidney induced for some reasons. The mechanisms of
nephrotic syndrome are still unclear, although the immune system might
be involved in present symptoms of nephrotic syndrome.
Recent studies demonstrated that the Rituximab (anti-human CD20 antibody) is a highly effective treatment for nephrotic syndrome. CD20 is widely expressed on B cells. Therefore, B cells might be involved in present symptoms of nephrotic syndrome.
We want to clarify the involvement of B cells on nephrotic syndrome, through the immune monitoring for pediatric patients with nephrotic syndrome who treat with the rituximab.
We are studying this research project in collaboration with Dr. Seiji Tanaka, Department of Pediatrics and child health, Kurume University school of Medicine. In addition, this research project is supported by a Grant-in Aid for Scientific Research (C).
腎臓は、血液をろ過し老廃物や塩分を尿として体外に追い出すと共に、体に必要なものを再吸収し体内に留めるというろ過機能を有している。ネフローゼ症候群は、これらの機能が何らかの原因で機能しなくなりタンパク尿、低アルブミン血症、浮腫などの症状を呈する。ネフローゼ症候群の発症には免疫機能の異常が大きく関与しているであろうと推測されているが、未だ発症のメカニズムについては多くの点が不明である。
近年、リツキシマブ（抗ヒトCD20抗体）がネフローゼ症候群に奏功することが報告されている。CD20分子は、主としてB細胞に発現することが知られていることから、ネフローゼ症候群の発症にB細胞が関与する可能性が考えられる。
本研究プロジェクトは、小児の難治性ネフローゼ症候群のリツキシマブ投与における免疫動態の解析を通して、ネフローゼ症候群におけるB細胞の関与を明らかにすることを目的として研究を遂行している。
なお、本研究プロジェクトは、本学小児科学講座・田中征治先生らとの共同研究であり、日本学術振興会科学研究費助成事業に採択された。
その他
・がん免疫に関する研究 Cancer Immunology
＝研究業績など（2013年以降）＝
2017
Yokomine, M., Matsueda, S., Kawano, K., Sasada, T., Fukui, A., Yamashita, T., Komatsu, N., Shichijo, S., Tasaki, K., Matsukuma, K., Itoh, K., Kamura, T., Ushijima, K.
Enhancement of humoral and cell mediated immune response to HPV16 L1-derived
peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like
particle vaccine in healthy females
(2017) Exp. Ther. Med., 13(4), pp. 1500-1505.
2016
Noguchi, M., Matsumoto, K., Uemura, H., Arai, G., Eto, M., Naito, S., Ohyama,
C., Nasu, Y., Tanaka, M., Moriya, F., Suekane, S., Matsueda, S., Komatsu,
N., Sasada, T., Yamada, A., Kakuma, T., Itoh, K.
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination
in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
(2016) Clin. Cancer Res., 22(1), p. 54-60.
Iwasa, S., Yamada, Y., Heike, Y., Shoji, H., Honma, Y., Komatsu, N., Matsueda,
S., Yamada, A., Morita, M., Yamaguchi, R., Tanaka, N., Kawahara, A., Kage,
M., Shichijo, S., Sasada, T., Itoh, K.
Phase I study of a new cancer vaccine of ten mixed peptides for advanced
cancer patients
(2016) Cancer Sci., 107(5), pp. 590-600.
2015
Yamada, T., Terazaki, Y., Sakamoto, S., Yoshiyama, K., Matsueda, S., Komatsu,
N., Waki, K., Yamada, A., Kawahara, A., Kage, M., Sugawara, S., Yamashita,
Y., Sasada, T., Takamori, S., Itoh, K.
Feasibility study of personalized peptide vaccination for advanced non-small
cell lung cancer patients who failed two or more treatment regimens
(2015) Int. J. Oncol., 46(1) pp. 55-62.
Noguchi, M., Arai, G., Matsumoto, K., Naito, S., Moriya, F., Suekane, S.,
Komatsu, N., Matsueda, S., Sasada, T., Yamada, A., Kakuma, T., Itoh, K.
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression
(2015) Cancer Immunol. Immunother., 64(4), pp. 493-505.
Araki, H., Pang, X., Komatsu, N., Soejima, M., Miyata, N., Takaki, M.,
Muta, S., Sasada, T., Noguchi, M., Koda, Y., Itoh, K., Kuhara, S., Tashiro,
K.
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for
peptide vaccine efficacy in castration-resistant prostate cancer patients
(2015) Cancer Immunol. Immunother., 64(12), pp. 1565-1573.
Yutani, S., Ueshima, K., Abe, K., Ishiguro, A., Eguchi, J., Matsueda, S., Komatsu, N., Shichijo, S., Yamada, A., Itoh, K., Sasada, T., Kudo, M., Noguchi, M.
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis
C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for
the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
(2015) J. Immunol. Res., 2015, pp. 473909.
2014
Kibe, S., Yutani, S., Motoyama, S., Nomura, T., Tanaka, N., Kawahara, A.,
Yamaguchi, T., Matsueda, S., Komatsu, N., Miura, M., Hinai, Y., Hattori,
S., Yamada, A., Kage, M., Itoh, K., Akagi, Y., Sasada, T.
Phase II study of personalized peptide vaccination for previously treated
advanced colorectal cancer
(2014) Cancer Immunol. Res., 2(12), pp. 1154-1162.
Waki, K., Yamada, T., Yoshiyama, K., Terazaki, Y., Sakamoto, S., Matsueda,
S., Komatsu, N., Sugawara, S., Takamori, S., Itoh, K., Yamada, A.
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis
in non-small cell lung cancer
(2014) Cancer Sci., 105(10) pp. 1229-1235.
Azuma, K., Komatsu, N.,Hattori, S.,Matsueda, S., Kawahara, A., Sasada,
T., Itoh, K., Hoshino, T.
Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib
(2014) PLoS One, 9(1), pp. e86667.
Soejima, M., Sagata, N., Komatsu, N., Sasada, T., Kawaguchi, A., Itoh,
K., Koda, Y.
Genetic factors associated with serum haptoglobin level in a Japanese population
(2014) Clinica Chimica Acta, 433, pp. 54-57.
2013
Matsueda, S., Komatsu, N., Kusumoto, K., Koga, S., Yamada, A., Kuromatsu, R., Yamada, S., Seki, R., Yutani, S., Shichijo, S., Mine, T., Fukuda, T., Okamura, T., Okuda, S., Sata, M., Honda, J., Kaji, M., Itoh, K., Sasada, T.
Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases
(2013) Developmental and Comparative Immunology, 41 (1), pp. 68-76.
Yutani, S., Komatsu, N., Yoshitomi, M., Matsueda, S., Yonemoto, K., Mine, T., Noguchi, M., Ishihara, Y., Yamada, A., Itoh, K., Sasada, T.
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
(2013) Oncology Reports, 30 (3), pp. 1094-1100.
Yutani, S., Komatsu, N., Matsueda, S., Yoshitomi, M., Shirahama, T., Yamada, A., Itoh, K., Sasada, T.
Juzentaihoto failed to augment antigen-specific immunity but prevented deterioration of patients' conditions in advanced pancreatic cancer under personalized peptide vaccine
(2013) Evidence-based Complementary and Alternative Medicine, 2013, art. no. 981717, .
Pang, X., Tashiro, K., Eguchi, R., Komatsu, N., Sasada, T., Itoh, K., Kuhara, S.
Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer
(2013) Bioscience, Biotechnology and Biochemistry, 77 (4), pp. 766-770.
Komatsu, N., Jackson, H.M., Chan, K.-F., Oveissi, S., Cebon, J., Itoh, K., Chen, W.
Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein
(2013) Molecular Immunology, 54 (3-4), pp. 465-471.
Komatsu, N., Matsueda, S., Noguchi, M., Yamada, A., Noguchi, M., Itoh, K., Sasada, T.
Personalized Peptide Vaccine as a Novel Immunotherapy Against Advanced Cancer
(2013) Molecular Vaccines, Part IV, pp. 361-369.
小松誠和、伊東恭悟
テーラーメイドペプチドワクチン ─個人の免疫記憶に基づくワクチン選択と治療
(2013) 実験医学増刊号, 31 (12), pp. 160-162.